Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): Primary analysis of Ph3 DeLLphi-304.

医学 化疗 肿瘤科 内科学 肺癌 癌症研究 病理
作者
Charles M. Rudin,Giannis Mountzios,Longhua Sun,Byoung Chul Cho,Umut Demırcı,Sofia Baka,Mahmut Gumus,Antonio Lugini,Tudor‐Eliade Ciuleanu,Myung‐Ju Ahn,Pedro Rocha,Bo Zhu,Fiona Blackhall,Tatsuya Yoshida,Taofeek K. Owonikoko,Luis Paz‐Ares,Shuang Huang,Diana Maria Gauto,Gonzálo Recondo,Martin Schüler
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:43 (17_suppl) 被引量:6
标识
DOI:10.1200/jco.2025.43.17_suppl.lba8008
摘要

LBA8008 Background: Tarlatamab, a bispecific T-cell engager (BiTE) immunotherapy, demonstrated promising activity in patients (pts) with previously treated SCLC in phase 1/2 trials. We report results from the primary analysis of the randomized controlled, phase 3 DeLLphi-304 study, evaluating tarlatamab vs CTx in pts with SCLC following progression on or after platinum-based chemotherapy. Methods: Pts were randomized 1:1 to tarlatamab or CTx (topotecan, lurbinectedin or amrubicin), stratified by prior treatment with a PD-(L)1 inhibitor, chemotherapy-free interval, brain metastases, and intended CTx. Primary endpoint was overall survival (OS). Key secondary endpoints were progression-free survival (PFS) and patient-reported outcomes (PRO). Other secondary endpoints included objective response rate (ORR), duration of response (DOR), disease control rate (DCR), and safety. Results: 509 pts were randomized (254, tarlatamab; 255, CTx). At median follow-up of 11.2 months (mo) for tarlatamab and 11.7 mo for CTx, pts in the tarlatamab arm had significantly longer OS (median OS: 13.6 vs 8.3 mo; hazard ratio [HR], 0.60 [95% CI: 0.47, 0.77]; P < 0.001) and PFS (median PFS: 4.2 vs 3.2 mo; HR, 0.72 [95% CI: 0.59, 0.88]; P < 0.001) vs pts in the CTx arm. Tarlatamab improved cancer-related symptoms of dyspnea and cough compared to CTx (Table). Lower rates of grade (Gr) ≥3 treatment-related adverse events (TRAEs) occurred with tarlatamab vs CTx (27% vs 62%); discontinuations due to TRAEs were lower with tarlatamab (3% vs 6%). The most common Gr ≥3 TRAEs were neutropenia (4%) and lymphopenia (4%) with tarlatamab and anemia (28%) and neutropenia (22%) with CTx. Cytokine release syndrome with tarlatamab was primarily low grade (42% Gr1; 13% Gr2; 1% Gr3) and manageable. Conclusions: The DeLLphi-304 trial showed tarlatamab significantly improved OS, PFS, and PROs, with a favorable safety and tolerability profile compared to CTx in pts with SCLC that progressed on or after initial platinum-based CTx, defining a new standard of care for these patients. Clinical Trial Information: NCT05740566; Legal entity responsible: Amgen Inc.; Funding: Amgen Inc.; Editorial acknowledgement: Medical writing support for the development of this abstract was provided by Sukanya Raghuraman, PhD, of Cactus Life Sciences, part of Cactus Communications, and was funded by Amgen Inc. Clinical trial information: NCT05740566 . Tarlatamab (n=254) CTx*(n=255) Tarlatamab treatment effect ( P -value) Median OS, mo (95% CI) 13.6 (11.1-NE) 8.3 (7.0-10.2) HR = 0.60 ( P < 0.001) Median PFS, mo (95% CI) 4.2 (3.0-4.4) 3.2 (2.9-4.2) HR = 0.72 ( P < 0.001) ORR, % (95% CI) 35 (29-41) 20 (16-26) Odds ratio = 2.13 Median DOR, mo (95% CI) 6.9 (4.5-12.4) 5.5 (4.2-5.7) — DCR, % (95% CI) 68 (62-74) 64 (58-70) — Dyspnea score, change from baseline after18 wks † , mean (95% CI) -1.94 (-4.32, 0.45) 7.20 (4.58-9.81) MD = -9.14 ( P < 0.001) Cough score, pts with improvement 18 wks after baseline ‡ , n (%) 41 (16) 23 (9) OR = 2.04 ( P = 0.012) Chest pain score, pts with improvement 18 wks after baseline ‡ , n (%) 22 (9) 9 (4) OR = 1.84 ( P = 0.100 § ) MD: mean difference; NE: not estimable; wks, weeks. *Topotecan (n=185), lurbinectedin (n=47), or amrubicin (n=23). †EORTC QLQ-C30 scale. ‡EORTC QLQ-LC13 scale. §Non-significant.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
减简发布了新的文献求助10
2秒前
搜集达人应助张张采纳,获得20
2秒前
ZNan完成签到 ,获得积分10
2秒前
car子发布了新的文献求助10
2秒前
我是老大应助大气夏瑶采纳,获得10
4秒前
Seagull发布了新的文献求助10
5秒前
大鱼大鱼完成签到,获得积分10
8秒前
华仔应助朱洪帆采纳,获得10
9秒前
张顺完成签到,获得积分10
9秒前
uuy完成签到,获得积分10
10秒前
11秒前
11秒前
Dalandal关注了科研通微信公众号
11秒前
11秒前
neu_zxy1991完成签到,获得积分10
12秒前
张江川发布了新的文献求助10
13秒前
梁耀栋发布了新的文献求助10
13秒前
KK_ad完成签到,获得积分10
14秒前
chenng完成签到,获得积分10
15秒前
栗子球完成签到,获得积分10
15秒前
研友_VZG7GZ应助Tine采纳,获得10
15秒前
我来了发布了新的文献求助10
16秒前
16秒前
鱼摸发布了新的文献求助30
16秒前
16秒前
嘻嘻哈哈应助个性的新竹采纳,获得10
16秒前
完美世界应助星星采纳,获得20
17秒前
17秒前
999完成签到,获得积分10
19秒前
hx完成签到 ,获得积分10
19秒前
19秒前
20秒前
21秒前
朱洪帆完成签到,获得积分20
21秒前
WEI发布了新的文献求助10
21秒前
852应助小密没有秘密采纳,获得10
21秒前
黎黎原上草完成签到,获得积分10
22秒前
23秒前
我是老大应助我来了采纳,获得10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场现状调查及投资机会研判报告 1000
2026年中国辛酸癸酸聚乙二醇甘油酯行业市场规模及竞争格局分析报告 1000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Resiliency Scale for Adolescents--Chinese Version 600
Matrix Methods in Data Mining and Pattern Recognition Second Edition 510
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7320005
求助须知:如何正确求助?哪些是违规求助? 8935706
关于积分的说明 18943034
捐赠科研通 6978457
什么是DOI,文献DOI怎么找? 3214430
关于科研通互助平台的介绍 2382323
邀请新用户注册赠送积分活动 2193521